Literature DB >> 1503626

Immunointervention with cyclosporin A in autoimmune neurological disorders.

R S Tindall1.   

Abstract

Cyclosporin A has proven a remarkably effective compound in suppressing disease activity in a number of animal models of autoimmune neurological disorders. During the last decade a number of controlled clinical trials have been carried out in human neurological disorders which are considered to be immune-mediated. The results of those trials are reviewed.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1503626     DOI： 10.1016/0896-8411(92)90048-u

Source DB:  PubMed          Journal:  J Autoimmun        ISSN： 0896-8411            Impact factor:   7.094


  2 in total

1.  Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.

Authors:  W Mahattanakul; T O Crawford; J W Griffin; J M Goldstein; D R Cornblath
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

2.  A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Authors:  Mamatha Pasnoor; Jianghua He; Laura Herbelin; Ted M Burns; Sharon Nations; Vera Bril; Annabel K Wang; Bakri H Elsheikh; John T Kissel; David Saperstein; J Aziz Shaibani; Carlayne Jackson; Andrea Swenson; James F Howard; Namita Goyal; William David; Matthew Wicklund; Michael Pulley; Mara Becker; Tahseen Mozaffar; Michael Benatar; Robert Pazcuzzi; Ericka Simpson; Jeffrey Rosenfeld; Mazen M Dimachkie; Jeffrey M Statland; Richard J Barohn
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.